Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 2/20 | 0.58 |
| ▸ | CDK8 | P49336 | 3/20 | 0.55 |
| ▸ | RAF1 | P04049 | 9/20 | 0.55 |
| ▸ | BRAF | P15056 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 3/20 | 0.52 |
| ▸ | CA7 | P43166 | 2/20 | 0.51 |
| ▸ | CA9 | Q16790 | 2/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | GRK2 | P25098 | 1/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5634693 | 0.92 | RET (0.61) | RETCDK8RAF1BRAFMEN1 | |
| SCHEMBL4445772 | 0.91 | CDK8 (0.56) | RETCDK8RAF1BRAFMAPT | |
| SCHEMBL4442142 | 0.90 | RAF1 (0.60) | RETCDK8RAF1BRAFMAPT | |
| SCHEMBL6030307 | 0.88 | RET (0.63) | RETCDK8RAF1BRAFMAPT | |
| SCHEMBL4444310 | 0.84 | RAF1 (0.60) | CDK8RAF1BRAFMAPTALDH1A1 | |
| SCHEMBL5634874 | 0.83 | RAF1 (0.61) | RETCDK8RAF1BRAFMEN1 | |
| SCHEMBL13648129 | 0.83 | RET (0.64) | RETCDK8RAF1BRAFMEN1 | |
| SCHEMBL5636194 | 0.82 | RAF1 (0.64) | RETCDK8RAF1BRAFMEN1 | |
| SCHEMBL101750 | 0.80 | RET (0.57) | RETCDK8RAF1BRAFMEN1 | |
| SCHEMBL3539364 | 0.79 | RAF1 (0.74) | RETCDK8RAF1BRAFMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163556-A1 | GLYCINAMIDE DERIVATIVES AS RAF-KINASE INHBITORS | BUCHSTALLER HANS-PETER | 2009-06-25 | — | — | US | disclosed |
| US-20090163556-A1 | GLYCINAMIDE DERIVATIVES AS RAF-KINASE INHBITORS | BUCHSTALLER HANS-PETER | 2009-06-25 | — | — | US | disclosed |
| US-20090163556-A1 | GLYCINAMIDE DERIVATIVES AS RAF-KINASE INHBITORS | BUCHSTALLER HANS-PETER | 2009-06-25 | — | — | US | disclosed |
| US-7476683-B2 | e.g. N-(4-Chloro-3-trifluoro methyl phenyl)-2-[3-(4-pyridinyloxy)phenyl amino]-acetamide; serine/threonine kinase inhibitor; anticarcinogenic, antiproliferative, antidiabetic agent; autoimmune diseases; atherosclerosis, arthritis, Crohn's disease, retinopaty | MERCK PATENT GMBH (DE) | 2009-01-13 | — | — | US | disclosed |
| US-7476683-B2 | e.g. N-(4-Chloro-3-trifluoro methyl phenyl)-2-[3-(4-pyridinyloxy)phenyl amino]-acetamide; serine/threonine kinase inhibitor; anticarcinogenic, antiproliferative, antidiabetic agent; autoimmune diseases; atherosclerosis, arthritis, Crohn's disease, retinopaty | MERCK PATENT GMBH (DE) | 2009-01-13 | — | — | US | disclosed |
| US-7476683-B2 | e.g. N-(4-Chloro-3-trifluoro methyl phenyl)-2-[3-(4-pyridinyloxy)phenyl amino]-acetamide; serine/threonine kinase inhibitor; anticarcinogenic, antiproliferative, antidiabetic agent; autoimmune diseases; atherosclerosis, arthritis, Crohn's disease, retinopaty | MERCK PATENT GMBH (DE) | 2009-01-13 | — | — | US | disclosed |
| EP-1531817-B1 | GLYCINAMIDE DERIVATIVES AS RAF-KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2008-07-30 | — | — | EP | disclosed |
| EP-1531817-B1 | GLYCINAMIDE DERIVATIVES AS RAF-KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2008-07-30 | — | — | EP | disclosed |
| US-20060167261-A1 | e.g. N-(4-Chloro-3-trifluoro methyl phenyl)-2-[3-(4-pyridinyloxy)phenyl amino]-acetamide; serine/threonine kinase inhibitor; anticarcinogenic, antiproliferative, antidiabetic agent; autoimmune diseases; atherosclerosis, arthritis, Crohn's disease, retinopaty | MERK PATENT GMBH (DE) | 2006-07-27 | — | — | US | disclosed |
| EP-1531817-A1 | GLYCINAMIDE DERIVATIVES AS RAF-KINASE INHIBITORS | MERCK PATENT GmbH (DE) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004019941-A1 | GLYCINAMIDE DERIVATIVES AS RAF-KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163556-A1 | GLYCINAMIDE DERIVATIVES AS RAF-KINASE INHBITORS | ARAF, BRAF, RAF1 | RET 106/4885CDK8 666/4885RAF1 3/4885 |
| US-20060167261-A1 | e.g. N-(4-Chloro-3-trifluoro methyl phenyl)-2-[3-(4-pyridinyloxy)phenyl amino]-acetamide; serine/threonine kinase inhibitor; anticarcinogenic, antiproliferative, antidiabetic agent; autoimmune diseases; atherosclerosis, arthritis, Crohn's disease, retinopaty | BRAF, RAF1, ARAF | RET 139/4885CDK8 270/4885RAF1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.